Black Diamond Therapeutics (BDTX) FCF Margin (2025)
Black Diamond Therapeutics (BDTX) posted FCF Margin of 76.36% for Q1 2025.
Black Diamond Therapeutics (BDTX) FCF Margin (2025) Analysis & Trends
Black Diamond Therapeutics' FCF Margin history runs 1 years deep, the most recent figure standing at 76.36% for Q1 2025.
- Quarterly FCF Margin changed N/A year-over-year to 76.36% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 42.56% (changed N/A YoY) and the FY2025 annual result came in at 42.56%, changed N/A from the prior year.
- FCF Margin was 76.36% for Q1 2025 at Black Diamond Therapeutics.
- Across five years, FCF Margin topped out at 76.36% in Q1 2025 and bottomed at 76.36% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Black Diamond Therapeutics | 99.59 Mn | -18.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 76.36% |